Breaking News, Collaborations & Alliances

MedImmune, SBI Biotech Enter Autoimmune Disease Research Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech’s anti-ILT7 protein for the potential treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. MedImmune will have global rights to any resulting product candidates and will be responsible for preclinical and clinical development, as well as all future development, manufacturing, sales and mar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters